- Home
- FCT vs MNPR Comparison
FCT vs MNPR Comparison
Compare FCT & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCT
- MNPR
- Stock Information
- Founded
- FCT 2004
- MNPR 2014
- Country
- FCT United States
- MNPR United States
- Employees
- FCT N/A
- MNPR N/A
- Industry
- FCT Finance Companies
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- FCT Finance
- MNPR Health Care
- Exchange
- FCT Nasdaq
- MNPR Nasdaq
- Market Cap
- FCT 270.4M
- MNPR 250.0M
- IPO Year
- FCT N/A
- MNPR 2019
- Fundamental
- Price
- FCT $10.38
- MNPR $40.25
- Analyst Decision
- FCT
- MNPR Strong Buy
- Analyst Count
- FCT 0
- MNPR 4
- Target Price
- FCT N/A
- MNPR $43.00
- AVG Volume (30 Days)
- FCT 106.8K
- MNPR 71.2K
- Earning Date
- FCT 01-01-0001
- MNPR 03-27-2025
- Dividend Yield
- FCT 11.29%
- MNPR N/A
- EPS Growth
- FCT N/A
- MNPR N/A
- EPS
- FCT N/A
- MNPR N/A
- Revenue
- FCT N/A
- MNPR N/A
- Revenue This Year
- FCT N/A
- MNPR N/A
- Revenue Next Year
- FCT N/A
- MNPR N/A
- P/E Ratio
- FCT N/A
- MNPR N/A
- Revenue Growth
- FCT N/A
- MNPR N/A
- 52 Week Low
- FCT $9.45
- MNPR $1.72
- 52 Week High
- FCT $10.42
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- FCT 48.73
- MNPR 49.34
- Support Level
- FCT $10.38
- MNPR $38.80
- Resistance Level
- FCT $10.47
- MNPR $45.60
- Average True Range (ATR)
- FCT 0.06
- MNPR 5.19
- MACD
- FCT -0.00
- MNPR -1.50
- Stochastic Oscillator
- FCT 22.86
- MNPR 9.37
About FCT First Trust Senior Floating Rate Income Fund II of Beneficial Interest
First Trust Senior Floating Rate Income Fund II is the United States based diversified, closed-end management investment company. Its investment objective is to seek a high level of current income. As a secondary objective, the fund attempts to preserve capital. The fund seeks to achieve the objectives by investing in a portfolio of senior floating-rate loan interests. Its portfolio of investments consists of aerospace and defense, agricultural products, broadcasting, cable and satellite, electric utilities and other sectors.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.